鸟嘌呤核苷酸驱动急性髓系白血病干细胞的核糖体生物发生与糖酵解重编程
维奈克拉耐药的急性髓系白血病干细胞通过上调鸟嘌呤核苷酸从头合成增强核糖体生物发生,抑制受损核糖体生物发生检查点,导致TP53不稳定和MYC持续表达,从而完成糖酵解重编程以绕过OXPHOS抑制。抑制IMPDH1/2可耗竭鸟嘌呤核苷酸、激活IRBC、稳定TP53、抑制MYC并损害糖酵解转换,削弱LSC干性并抑制人AML细胞异种移植重建,且该效应与维奈克拉耐药或TP53突变状态无关。
要点
- 维奈克拉耐药LSC发生糖酵解重编程以绕过OXPHOS抑制。
- 鸟嘌呤核苷酸从头合成增强支持核糖体生物发生并抑制IRBC,导致TP53不稳定和MYC持续表达。
- 抑制IMPDH1/2可耗竭鸟嘌呤核苷酸、激活IRBC、稳定TP53、抑制MYC并损害糖酵解转换,削弱LSC干性。
核心结论
- 维奈克拉耐药LSC通过鸟嘌呤核苷酸驱动的核糖体生物发生和糖酵解重编程绕过OXPHOS抑制,靶向鸟嘌呤核苷酸生物合成可能成为根除治疗耐药LSC的临床可行策略。
研究设计与样本
- 研究采用维奈克拉耐药LSC模型,结合异种移植实验评估人AML细胞重建能力,并分析TP53突变状态与维奈克拉耐药对LSC干性的影响。
主要发现
- 维奈克拉耐药LSC发生糖酵解重编程以绕过OXPHOS抑制,该代谢转换由增强的核糖体生物发生支持,后者由上调的鸟嘌呤核苷酸从头合成维持。
- 丰富的鸟嘌呤核苷酸抑制受损核糖体生物发生检查点(IRBC),导致TP53不稳定和MYC持续表达。
- 抑制IMPDH1/2耗竭鸟嘌呤核苷酸、激活IRBC、稳定TP53、抑制MYC并损害向糖酵解的代谢转换。
- 该代谢重编程破坏LSC干性并抑制人AML细胞在异种移植实验中的重建。
- 无论维奈克拉耐药或AML细胞TP53突变状态如何,均观察到LSC干性受抑制。
临床怎么用
- 作者认为靶向鸟嘌呤核苷酸生物合成可能提供一种临床可行的策略以根除治疗耐药LSC。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metabolic adaptation. Although venetoclax (Ven) inhibits oxidative phosphorylation (OXPHOS), we found that Ven-resistant LSC undergo glycolytic reprogramming to bypass OXPHOS inhibition. This metabolic shift is supported by enhanced ribosome biogenesis, which is sustained by upregulated de novo guanine nucleotide biosynthesis. Abundant guanine nucleotides suppress the impaired ribosome biogenesis checkpoint (IRBC), leading to TP53 destabilization and persistent MYC expression. The inhibition of inosine monophosphate dehydrogenases (IMPDH1/2) depletes guanine nucleotides, activates IRBC, stabilizes TP53, represses MYC, and impairs the metabolic shift to glycolysis. This metabolic rewiring disrupts LSC stemness and suppresses the reconstitution of human AML cells in xenotransplantation experiments. Notably, the suppression of LSC stemness was observed regardless of Ven resistance or the TP53 mutational status of AML cells. These findings reveal that mutation-independent TP53 inactivation is involved in resistant AML and suggest that targeting guanine nucleotide biosynthesis may offer a clinically actionable strategy to eradicate therapy-resistant LSC.
引用
- Kawano G, Ikeda R, Ishihara D, et al. Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells. Blood. 2026. PMID: 41191529. doi:10.1182/blood.2025030209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。